Latest news with #RoyBuchanan
Yahoo
06-07-2025
- Business
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Insider
27-05-2025
- Business
- Business Insider
Citizens JMP Sticks to Their Buy Rating for Cidara Therapeutics (CDTX)
In a report released today, Roy Buchanan from Citizens JMP maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $47.00. The company's shares closed last Friday at $24.28. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Buchanan covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Inovio Pharmaceuticals, and Arbutus Biopharma. According to TipRanks, Buchanan has an average return of -26.6% and a 26.50% success rate on recommended stocks. Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $40.40, a 66.39% upside from current levels. In a report released on May 23, Needham also maintained a Buy rating on the stock with a $35.00 price target.
